Expert Interview
Discussing primary ITP and the potential of VYVGART (efgartigimod)
Ticker(s): ARGXInstitution: Weill Cornell
- Emeritus Professor of Pediatrics, Medicine and Obstetrics and Gynecology at Weill Cornell Medicine
- Clinical and clinical research interests have been largely in Immune ThrombocytoPenia (ITP) and Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).
- He has published over 400 manuscripts predominantly in these areas.
Roughly how many patients with ITP do you currently manage?
Added By: user1ae2bf5fWill efgartigimod be used for IGIV failures only? What is an IGIV failure? How many pts fail IGIV?
Added By: folksyCan Ultomiris or Soliris be used instead of Fcrn?
Added By: folksyPlease describe how you currently manage patients with ITP
Added By: user1ae2bf5fAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
